LEADER 04753nam 2200829Ia 450 001 9910957499303321 005 20251017110101.0 010 $a9786610176366 010 $a9780309166515 010 $a0309166519 010 $a9781280176364 010 $a1280176369 010 $a9780309530330 010 $a0309530334 035 $a(CKB)111090425020484 035 $a(OCoLC)55636256 035 $a(CaPaEBR)ebrary10055384 035 $a(SSID)ssj0000163067 035 $a(PQKBManifestationID)11180766 035 $a(PQKBTitleCode)TC0000163067 035 $a(PQKBWorkID)10108429 035 $a(PQKB)10508222 035 $a(Au-PeEL)EBL3376295 035 $a(CaPaEBR)ebr10055384 035 $a(OCoLC)923262669 035 $a(MiAaPQ)EBC3376295 035 $a(Perlego)4732854 035 $a(DNLM)1209809 035 $a(BIP)10228840 035 $a(EXLCZ)99111090425020484 100 $a20040311d2004 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aGiving full measure to countermeasures $eaddressing problems in the DOD program to develop medical countermeasures against biological warfare agents /$fCommittee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences ; Lois M. Joellenbeck, Jane S. Durch, and Leslie Z. Benet, editors 205 $a1st ed. 210 $aWashington, DC $cNational Academies Press$dc2004 215 $a1 online resource (160 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$a9780309091534 311 08$a0309091535 320 $aIncludes bibliographical references. 327 $aFrontMatter -- Reviewers -- Preface -- Contents -- Figures, Tables, and Boxes -- Abbreviations and Acronyms -- Executive Summary -- 1 Ending Half-Measures for Countermeasures: The Challenge and Major Recommendations -- 2 Organizing Research and Development for Medical Countermeasures to Accomplish Essential Functions -- 3 Challenges in the Research and Development of Medical Countermeasures Against Biological Warfare Agents -- APPENDIXES -- APPENDIX A Background: The Current DoD Medical Biowarfare Countermeasures Program -- APPENDIX B Agendas for Information-Gathering Meetings -- APPENDIX C Acknowledgments -- APPENDIX D Biographical Sketches. 330 $aIn recent years, substantial efforts have been initiated to develop new drugs, vaccines, and other medical interventions against biological agents that could be used in bioterrorist attacks against civilian populations. According to a new congressionally mandated report from the Institute of Medicine and National Research Council of the National Academies, to successfully develop these drugs, vaccines, and other medical interventions against biowarfare agents, Congress should authorize the creation of a new agency within the Office of the Secretary of the U.S. Department of Defense. The committee recommended that Congress should improve liability protections for those who develop and manufacture these products, to stimulate willingness to invest in new research and development for biowarfare protection. Giving Full Measure to Countermeasures also identifies other challenges "such as the need for appropriate animal models and laboratories equipped with high-level biosafety protections "that will require attention if DoD efforts to develop new medical countermeasures are to be successful. 606 $aBiological warfare$xHealth aspects$zUnited States 606 $aBiological warfare$zUnited States$xSafety measures 606 $aBiological weapons$xHealth aspects$zUnited States 606 $aBiological weapons$zUnited States$xSafety measures 606 $aMedicine, Preventive$zUnited States 606 $aAntitoxins$zUnited States 606 $aVaccines$zUnited States 615 0$aBiological warfare$xHealth aspects 615 0$aBiological warfare$xSafety measures. 615 0$aBiological weapons$xHealth aspects 615 0$aBiological weapons$xSafety measures. 615 0$aMedicine, Preventive 615 0$aAntitoxins 615 0$aVaccines 676 $a358/.38 701 $aJoellenbeck$b Lois M$g(Lois Mary),$f1963-$01804997 701 $aDurch$b Jane$01092318 701 $aBenet$b Leslie Z$096362 712 02$aCommittee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures against Biological Warfare Agents, 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910957499303321 996 $aGiving full measure to countermeasures$94356765 997 $aUNINA